" class="no-js "lang="en-US"> Novavax to Participate in Fireside Chat at Goldman Sachs Virtual Conference - Medtech Alert
Thursday, May 23, 2024

Novavax to Participate in Fireside Chat at Goldman Sachs Virtual Conference

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in a fireside chat during the Goldman Sachs Recovery Inoculated: The Current Outlook for COVID-19 Vaccines, Treatments, Testing and the Economy virtual conference. Novavax’ COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion.

Fireside chat details:
Date: Tuesday, April 13, 2021
Time: 2:30 – 3:20 p.m. Eastern Time (ET)
Panel title: COVID-19 Vaccines – Staying Ahead of the Curve
Novavax participant: Vivek Shinde, M.D., M.P.H., Vice President, Clinical Development
This event is open to Goldman Sachs clients.

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more